<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SEROMYCINÂ - cycloserineÂ capsuleÂ </strong><br>Purdue GMP Center LLC dba The Chao Center<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION SECTION</h1>
<p class="First"><br>Seromycin (Cycloserine Capsules, USP), 3-isoxazolidinone, 4-amino â€“, (R)â€“ is a broadâ€“spectrum antibiotic that is produced by a <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of Streptomyces orchidaceus and has also been synthesized. Cycloserine is a white to offâ€“white powder that is soluble in water and stable in alkaline solution. It is rapidly destroyed at a neutral or acid pH.Â  <br>Â <br>Cycloserine has a pH between 5.5 and 6.5 in a solution containing 100 mg/mL. The molecular weight of cycloserine is 102.09, and it has an empirical formula of C3H6N2O2.Â  <br></p>
<br><p><br></p>
<p><br></p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="51727-6">
<a name="section-2"></a><p></p>
<h1>INACTIVE INGREDIENT SECTION</h1>
<p class="First">Each capsule contains cycloserine, 250Â mg (2.45Â mmol); D and CÂ Yellow No.Â 10, FD 
and CÂ Blue No.Â 1, FD and CÂ Red No.Â 3, FD and CÂ Yellow No.Â 6, gelatin, iron 
oxide, talc, titanium dioxide, and other inactive ingredients.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY SECTION</h1>
<p class="First">After oral administration, cycloserine is readily absorbed from 
the gastrointestinal tract, with peak blood levels occurring in 4Â to 8Â hours. 
Blood levels of 25Â to 30Â Î¼g/mL can generally be maintained with the usual dosage 
of 250Â mg twice a day, although the relationship of plasma levels to dosage is 
not always consistent. Concentrations in the cerebrospinal fluid, pleural fluid, 
fetal blood, and motherâ€™s milk approach those found in the serum. Detectable 
amounts are found in ascitic fluid, bile, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, amniotic fluid, and lung and 
lymph tissues. Approximately 65 percent of a single dose of cycloserine can be 
recovered in the urine within 72Â hours after oral administration. The remaining 
35 percent is apparently metabolized to unknown substances. The maximum 
excretion rate occurs 2Â to 6Â hours after administration, with 50 percent of the 
drug eliminated in 12Â hours. </p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-4"></a><p></p>
<h1>MICROBIOLOGY SECTION</h1>
<p class="First">Cycloserine inhibits cellâ€“wall synthesis in susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> 
of gramâ€“positive and gramâ€“negative bacteria and in <span class="Italics">Mycobacterium <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span></span>. </p>Susceptibility 
Tests
<p>Cycloserine clinical laboratory standard powder is available for both direct 
and indirect methods<span class="Sup">1</span> of determining the susceptibility 
of <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of mycobacteria. Cycloserine MICsÂ for susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are 
25Â Î¼g/mL or lower. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS &amp; USAGE SECTION</h1>
<p class="First">Seromycin is indicated in the treatment of active pulmonary and 
<span class="product-label-link" type="condition" conceptid="4310580" conceptname="Tuberculosis, extrapulmonary">extrapulmonary tuberculosis</span> (including <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>) when the causative 
organisms are susceptible to this drug and when treatment with the primary 
medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved 
inadequate. Like all antituberculosis drugs, Seromycin should be administered in 
conjunction with other effective chemotherapy and not as the sole therapeutic 
agent. </p>
<p>Seromycin may be effective in the treatment of acute <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> 
caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of gramâ€“positive and gramâ€“negative bacteria, 
especially <span class="Italics">Enterobacter</span>Â spp. and <span class="Italics">Escherichia coli</span>. It is generally no more and is usually 
less effective than other antimicrobial agents in the treatment of urinary tract 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by bacteria other than mycobacteria. Use of Seromycin in these 
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> should be considered only when more conventional therapy has failed 
and when the organism has been demonstrated to be susceptible to the drug. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS SECTION</h1>
<p class="First">Administration is contraindicated in patients with any of the 
following: </p>
<p>Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to cycloserine</p>
<p>Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></p>
<p>Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, severe <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span></p>
<p>Â Â Â Â Â Â Severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span></p>
<p>Â Â Â Â Â Â Excessive concurrent use of alcohol</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS SECTION</h1>
<p class="First">Administration of Seromycin should be discontinued or the dosage 
reduced if the patient develops <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span> or symptoms of CNSÂ toxicity, 
such as <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, 
<span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, or <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>. </p>
<p>The toxicity of Seromycin is closely related to excessive blood levelsÂ (above 
30Â Î¼g/mL), as determined by high dosage or inadequate renal clearance. The ratio 
of toxic dose to effective dose in <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> is small. </p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> is increased in chronic alcoholics.</p>
<p>Patients should be monitored by hematologic, renal excretion, blood level, 
and liver function studies. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS SECTION</h1>
<p class="First">Before treatment with Seromycin is initiated, cultures should be 
taken and the organismâ€™s susceptibility to the drug should be established. In 
tuberculous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the organismâ€™s susceptibility to the other 
antituberculosis agents in the regimen should also be demonstrated. </p>
<p>Anticonvulsant drugs or sedatives may be effective in controlling symptoms of 
CNSÂ toxicity, such as <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. Patients receiving more 
than 500Â mg of Seromycin daily should be closely observed for such symptoms. The 
value of pyridoxine in preventing CNSÂ toxicity from Seromycin has not been 
proved. </p>
<p>Administration of Seromycin and other antituberculosis drugs has been 
associated in a few instances with vitaminÂ B<span class="Sub">12</span> and/or 
folicâ€“acid deficiency, <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="432282" conceptname="Sideroblastic anemia">sideroblastic anemia</span>. If 
evidence of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> develops during treatment, appropriate studies and therapy 
should be instituted. </p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-9"></a><p></p>
<h1>LABORATORY TESTS SECTION</h1>
<p class="First">Blood levels should be determined at least weekly for patients 
with reduced renal function, for individuals receiving a daily dosage of more 
than 500Â mg, and for those showing signs and symptoms suggestive of toxicity. 
The dosage should be adjusted to keep the blood level below 30Â Î¼g/mL. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-10"></a><p></p>
<h1>DRUG INTERACTIONS SECTION</h1>
<p class="First">Concurrent administration of ethionamide has been reported to 
potentiate neurotoxic side effects. </p>
<p>Alcohol and Seromycin are incompatible, especially during a regimen calling 
for large doses of the latter. Alcohol increases the possibility and risk of 
epileptic episodes. </p>
<p>Concurrent administration of isoniazid may result in increased incidence of 
CNSÂ effects, such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Dosage adjustments may be 
necessary and patients should be monitored closely for signs of CNSÂ toxicity. 
</p>Carcinogenesis, 
Mutagenicity, and Impairment of Fertility 
<p>Studies have not been performed to determine potential for carcinogenicity. 
The Ames test and unscheduled DNAÂ repair test were negative. A study in 
2Â generations of rats showed no impairment of fertility relative to controls for 
the first mating but somewhat lower fertility in the second mating. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-11"></a><p></p>
<h1>PREGNANCY SECTION</h1>
<p class="First">Pregnancy Category C 
</p>
<p>A study in 2Â generations of rats given doses up to 100Â mg/kg/day 
demonstrated no teratogenic effect in offspring. It is not known whether cycloserine can cause fetal harm when administered to a pregnant woman or can 
affect reproduction capacity. Seromycin should be given to a pregnant woman only 
if clearly needed. </p>
<br>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-12"></a><p></p>
<h1>NURSING MOTHERS SECTION</h1>
<p class="First">Because of the potential for serious adverse reactions in nursing infants from 
Seromycin, a decision should be made whether to discontinue nursing or to 
discontinue the drug, taking into account the importance of the drug to the 
mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-13"></a><p></p>
<h1>PEDIATRIC USE SECTION</h1>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-14"></a><p></p>
<h1>ADVERSE REACTIONS SECTION</h1>
<p class="First">Most adverse reactions occurring during therapy with Seromycin 
involve the nervous system or are manifestations of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span>. The 
following side effects have been observed in patients receiving Seromycin: 
</p>
<a href="http://"></a><a name="i29fd1770-b404-49e2-8f8b-45f39b6de18b"></a><table width="544">
<col align="left">
<col align="left">
<tbody class="Headless">
<tr class="First"><td align="left"><p class="First"><span class="Bold">Nervous system symptoms</span> (which appear to 
be related to higher dosages of the drug, i.e.,Â more than 500Â mg daily) 
</p></td></tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">Dysarthria</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> and <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> with <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">loss of memory</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First">Psychoses, possibly with suicidal tendencies</p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">Character changes</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First">Hyperirritability</p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggression</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">Paresis</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">Hyperreflexia</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First">Major and minor (localized) <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span></p></td>
</tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First"><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span></p></td>
</tr>
<tr><td align="left"><p class="First"><span class="Bold">Cardiovascular</span></p></td></tr>
<tr>
<td align="left"><br></td>
<td align="left"><p class="First">Sudden development of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in patients 
receiving 1Â to 1.5Â g of Seromycin daily has been reported </p></td>
</tr>
<tr><td align="left"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></span> (apparently not related to 
dosage) </p></td></tr>
<tr><td align="left"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span></span></p></td></tr>
<tr><td align="left"><p class="First"><span class="Bold">Miscellaneous</span></p></td></tr>
<tr class="Last">
<td align="left"><br></td>
<td align="left"><p class="First">Elevated serum transaminase, especially in patients with 
preexisting liver disease</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-15"></a><p></p>
<h1>OVERDOSAGE SECTION</h1>
<p class="First">Acute toxicity from cycloserine can occur if more than 1Â g is 
ingested by an adult. Chronic toxicity from cycloserine is dose related and can 
occur if more than 500Â mg is administered daily. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> 
will accumulate cycloserine and may develop toxicity if the dosing regimen is 
not modified. Patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should not receive the drug. 
The central nervous system is the most common organ system involved with 
toxicity. Toxic effects may include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, 
hyperirritability, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. Following larger 
ingestions, <span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">paresis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> often occur. Ethyl alcohol may 
increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients receiving cycloserine. </p>
<p>The oral median lethal dose in mice is 5290Â mg/kg.</p>Treatment
<p>To obtain upâ€“toâ€“date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good 
resource is your certified Regional Poison Control Center. Telephone numbers of 
certified poison control centers are listed in the <span class="Italics">Physiciansâ€™ Desk ReferenceÂ (PDR)</span>. In managing overdosage, 
consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, 
and unusual drug kinetics in your patient. </p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> of cycloserine have been reported rarely. The following is provided 
to serve as a guide should such an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> be encountered. </p>
<p>Protect the patientâ€™s airway and support ventilation and perfusion. 
Meticulously monitor and maintain, within acceptable limits, the patientâ€™s vital 
signs, blood gases, serum electrolytes,Â etc. Absorption of drugs from the 
gastrointestinal tract may be decreased by giving activated charcoal, which, in 
many cases, is more effective than <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or lavage; consider charcoal instead 
of or in addition to gastric emptying. Repeated doses of charcoal over time may 
hasten elimination of some drugs that have been absorbed. Safeguard the 
patientâ€™s airway when employing gastric emptying or charcoal. </p>
<p>In adults, many of the neurotoxic effects of cycloserine can be both treated 
and prevented with the administration of 200Â to 300Â mg of pyridoxine daily. </p>
<p>The use of hemodialysis has been shown to remove cycloserine from the 
bloodstream. This procedure should be reserved for patients with 
life-threatening toxicity that is unresponsive to less invasive therapy. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-16"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION SECTION</h1>
<p class="First">Seromycin is effective orally and is currently administered only by this route. 
The usual dosage is 500Â mg to 1Â g daily in divided doses monitored by blood 
levels.<span class="Sup">2</span> The initial adult dosage most frequently given 
is 250Â mg twice daily at 12â€“hour intervals for the firstÂ 2 weeks. A daily dosage 
of 1Â g should not be exceeded.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-17"></a><p></p>
<h1>HOW SUPPLIED SECTION</h1>
<p class="First">Seromycin<span class="Sup"></span> is available as a 250 mg capsule 
with an opaque red cap and opaque gray body imprinted with â€œCHAOâ€? andÂ â€œF04â€? in 
edible black ink on both the cap and the body. </p>
<p>Â Â Â BottlesÂ ofÂ 40Â  NDC 13845-1200-3<br></p>
<p>Store at controlled room temperature, 20Â°Â toÂ 25Â°C (68Â°Â toÂ 77Â°F) [seeÂ USP]. 
</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-18"></a><p></p>
<h1>REFERENCES SECTION</h1>
<p class="First">1. Kubica GP, Dye WE: Laboratory methods for clinical and public health - mycobacteriology, US Department of Health, Education, and Welfare, Public Health Services, 1967, pp47-55, 66-70.</p>
<p>2. Jones LR: Colorimetric determination of cycloserine, a new antibiotic. Anal Chem 1956; 28:39.</p>
<p>The Chao Center for Industrial Pharmacy and Contact ManufacturingÂ  West Lafayette, IN, 47906, USA</p>
<p>Literature revised 14 JANUARY 2009</p>
<p>LM000251.00Â  PRINTED IN USA<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PACKAGE LABEL PRINCIPAL DISPLAY PANEL</h1>
<p class="First">SEROMYCINÂ  cycloSERINE Capsules, USPÂ  250mgÂ  THE CHAO CENTERÂ  NDC 13845-1200-3Â  40 capsules Rx only<br><br>Usual Initial Adult Dose: One capsule (250 mg) twice a day at 12 hour intervals. See accompanying literature. Dispense in a tight container.<br><br>WARNING: Potent drug. May cause serious reactions in some individuals. Use in patients under close medical supervision. Read accompanying literature before using.<br><br>13845-1200-3<br><br>LM000250.00<br><br>Keep tightly closed. Store at controlled room temperature, 20 degreesÂ  to 25 degrees C (68 degrees to 77 degrees F). [see USP]<br><br>MaunfactureÂ  The Chao center for Industrial Pharmacy and Contract Manufacturing, West Lafayette, IN 47906, USA<br><br>Expiration DateÂ  Batch No.</p>
<p><img alt="PURDUE GMP SEROMYCIN LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1e08327-4b90-463e-bb2a-22438cabcef2&amp;name=Purdue_GMP_seromycin.jpg"></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SEROMYCINÂ 		
					</strong><br><span class="contentTableReg">cycloserine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:13845-1200</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYCLOSERINE</strong> (CYCLOSERINE) </td>
<td class="formItem">CYCLOSERINE</td>
<td class="formItem">250Â mg Â inÂ 250Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PROPIONATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red (Opaque Red 353) ,Â gray (Opaque Grey 284) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CHAOFO4) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CHAOFO4</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:13845-1200-3</td>
<td class="formItem">40  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:13845-1200-1</td>
<td class="formItem">250 mg in 1 CAPSULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA060593</td>
<td class="formItem">03/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Purdue GMP Center LLC dba The Chao Center
							(159802532)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Purdue GMP Center LLC dba The Chao Center (159802532)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e9dc169f-0f00-411c-9c3e-4ea7b9e85392</div>
<div>Set id: e1e08327-4b90-463e-bb2a-22438cabcef2</div>
<div>Version: 2</div>
<div>Effective Time: 20111005</div>
</div>
</div>Â <div class="DistributorName">Purdue GMP Center LLC dba The Chao Center</div></p>
</body></html>
